Navigation Links
DARA BioSciences, Inc. Announces Appointment of New Director to Board

RALEIGH, N.C., Feb. 27 /PRNewswire-FirstCall/ -- DARA BioSciences(TM) (Nasdaq: DARA) announced today the appointment of Haywood D. Cochrane, Jr. to the Board of Directors. Mr. Cochrane was appointed to fill a Board vacancy and will serve on the Company's Audit and Compensation Committees. The appointment was effective February 21, 2008.

In making the announcement DARA's Board Chairman, Richard Franco, Sr., commented, "We are pleased that Haywood has joined us as a Director. His vast knowledge and successful experience in the healthcare industry will further strengthen DARA's already skilled Board."

Mr. Cochrane is currently Vice Chairman and a Director of I-trax, Inc. (Amex: DMX), a publicly traded, total population health management and productivity company. Mr. Cochrane has previously served as a Director of seven other publicly-traded companies.

About DARA BioSciences, Inc.

DARA BioSciences(TM), Inc. ("DARA") is a Raleigh, North Carolina-based development-stage pharmaceutical company that acquires promising therapeutic molecules and medical technologies directly or through investment in established companies. DARA focuses its therapeutic development efforts on small molecules from late preclinical development through phase 2 clinical trials. DARA is developing a portfolio of therapeutic candidates for neuropathic pain, metabolic diseases including type 2 diabetes, dyslipidemia and dermatological disorders. DARA has licensed promising drug development candidates from Kirin Pharmaceuticals of Japan, Bayer Pharmaceuticals Corporation, Massachusetts General Hospital and Nuada LLC.

For more information please contact the Company at 919-872-5578 or visit our web site at

All statements in this news release that are not historical are forward-looking statements within the meaning of the Securities Exchange Act of 1934 as amended. Such forward-looking statements are subject to factors that could cause actual results to differ materially for DARA from those projected. Those factors include risks and uncertainties relating to the company's ability to develop and bring new products to market as anticipated, the current regulatory environment in which the company develops and sells its products, the market acceptance of those products, dependence on partner, successful performance under collaborative and other commercial agreements, competition, the strength of DARA's intellectual property, the intellectual property of others and other risk factors identified in the documents DARA has filed, or will file, with the Securities and Exchange Commission. Copies of DARA's filings with the SEC may be obtained from the SEC Internet site at DARA expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in DARA's expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based. DARA BioSciences and the DARA logo are trademarks of DARA BioSciences, Inc.

SOURCE DARA BioSciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Ardea Biosciences, Inc. Reports Third Quarter 2007 Operating and Financial Results
2. Pressure BioSciences, Inc. Provides Corporate Update
3. Founder of ILEX Oncology and Triton Biosciences, Richard Love, Joins Board of Directors of Cell Therapeutics, Inc. (CTI)
4. Pressure BioSciences, Inc. Announces CE Mark Approval and Compliance with the IEC 61010-1 Standard for a Second PCT-based Instrument, the Barocycler NEP2320
5. Pressure BioSciences, Inc. Issued First Patent in Canada
6. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update
8. Selection of Development Candidate Triggers $0.5 Million Milestone Payment to Ardea Biosciences, Inc.
9. Forest Laboratories, Inc. Announces Amendment to Bystolic(TM) (nebivolol) Agreement
10. Mylan Announces Amendment to Bystolic(TM) (Nebivolol) Agreement
11. ZARS Pharma Announces Marketing Authorization of Rapydan(R) in Europe
Post Your Comments:
(Date:10/12/2017)... ... October 12, 2017 , ... DuPont ... today that they have entered into a multiyear collaboration to identify and characterize ... with additional tools for gene editing across all applications. , Under the terms ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... partners with the pharmaceutical and biotechnology industries to improve patient outcomes and quality ... Several trends in analytical testing are being attributed to new regulatory requirements for ...
(Date:10/11/2017)... ... October 11, 2017 , ... ... in its endogenous context, enabling overexpression experiments and avoiding the use of exogenous ... RNA guides is transformative for performing systematic gain-of-function studies. , This complement ...
(Date:10/11/2017)... BALTIMORE, Md. (PRWEB) , ... October 11, 2017 ... ... for digital pathology, announced today it will be hosting a Webinar titled, “Pathology ... of  Advanced Pathology Associates , on digital pathology adoption best practices and how ...
Breaking Biology Technology:
(Date:8/15/2017)... Va. , Aug. 15 2017   ivWatch LLC , ... of intravenous (IV) therapy, today announced receipt of its ISO 13485 ... developed by the International Organization for Standardization (ISO®). ... ivWatch Model 400 Continuous Monitoring device for the ... "This is ...
(Date:6/14/2017)... June 15, 2017  IBM (NYSE: IBM ) is introducing ... event dedicated to developing collaboration between startups and global businesses, ... 15-17. During the event, nine startups will showcase the solutions ... various industries. France ... market, with a 30 percent increase in the number of ...
(Date:5/6/2017)... SINGAPORE , May 5, 2017 ... has just announced a new breakthrough in biometric ... that exploits quantum mechanical properties to perform ... new smart semiconductor material created by Ram Group ... across finance, entertainment, transportation, supply chains and security. ...
Breaking Biology News(10 mins):